CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SINEW Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SINEW Pharma Inc
14F-5
No.3, Yuanqu Street, Nangang District
Phone: +886 227885365p:+886 227885365 TAIPEI, 115  Taiwan Ticker: 66346634
Business Summary
Sinew Pharma Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of liver disease treatment drugs and pain medication. The Company's main products include fatty liver disease treatment drugs SNP-610, SNP-630, no hepatotoxicity painkillers SNP-810 and antidote SNP-820. The Company's products are in clinical trials.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager KaiminZhu
Deputy General Manager, Chief Research & Development Officer, Director ZhenghuiXiong
Head of Finance & Accounting ZiwenChen 6/29/2020 6/29/2020
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 52 (As of 12/31/2023)
Outstanding Shares: 71,333,975 (As of 8/5/2024)
Shareholders: 2,265
Stock Exchange: TPO
Fax Number: +886 227885382


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024